More than 1,000 Clinicians Observe Implantation of Unique Stent System for Difficult-to-Treat Coronary Artery Disease

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced today the transmission of a live satellite feed of a clinical case performed in the United Kingdom to an audience of more than 1,000 interventional cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco.

The procedure was performed at The London Chest Hospital by Simon Kennon, M.D., FRCP.

“The Tryton stent design means that it is both deliverable and re-crossable,” said Dr. Kennon. “In my practice, it is now the default two-stent strategy for bifurcations.”

“We are pleased that the Tryton Stent System was selected to be featured as one of the live case demonstrations at TCT, one of the world’s premier conferences for interventional cardiologists,” said J. Greg Davis, president and CEO of Tryton Medical. “We have had a great deal of interest about the product at our booth on the exhibition floor at the meeting, and it has been a pleasure to share our enthusiasm for the Tryton solution with the many international clinicians attending TCT this year.

“By the end of next week more than 300 Tryton Stent Systems will have been used to treat some of the most difficult cases in interventional cardiology.”

About the Tryton Side Branch Stent System

The Tryton Side Branch Stent System is designed to offer a dedicated strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation. These areas of the vascular system are a common location for plaque and are particularly challenging to treat with currently available stent systems. Approximately twenty percent of patients treated for coronary artery disease have diseased bifurcated lesions.

Tryton’s highly deliverable cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.

The Tryton Side Branch Stent System demonstrated excellent six-month clinical results in a first-in-man study of the system in 30 patients, with no restenosis occurring in the side branch artery. The stent system has received CE Mark approval in Europe and is not approved in the United States.

About Tryton Medical, Inc.

Tryton Medical, Inc., located in Durham, N.C., is a leading developer of novel stent systems for the treatment of bifurcation lesions. The company''s Side Branch Stent System, approved for sale in Europe, is designed to offer a dedicated strategy for treating these challenging cases. The privately held company is backed by Spray Ventures, PTV Sciences, and RiverVest Ventures. For more information please visit www.trytonmedical.com.

Contacts:

Nicole Osmer Healthcare Communications
Nicole Osmer, 650-454-0504